# OnCo record uterine-carcinosarcoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/uterine-carcinosarcoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "uterine-carcinosarcoma" ;
  schema:name "Uterine carcinosarcoma"@en ;
  schema:alternateName "Malignant mixed Mullerian tumour"@en, "MMMT"@en, "Endometrial carcinosarcoma"@en ;
  schema:description "Uterine carcinosarcoma is a two-faced cancer with a carcinoma part and a sarcoma-like part that both come from the same faulty epithelial cell. It is treated as a high-grade endometrial cancer, with surgery, carboplatin-paclitaxel and often radiotherapy, and its frequent HER2 expression is opening a route to antibody-drug conjugates."@en ;
  schema:url <https://onco.cc/cancers/uterine-carcinosarcoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Uterine_carcinosarcoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Uterine_carcinosarcoma> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/targets/wee1/>, <https://onco.cc/targets/atr/>, <https://onco.cc/ideas/idea-her2-adc-serous-endometrial/> ;
  onco:standardOfCare <https://onco.cc/terms/hysterectomy/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/trials/portec-3/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/trials/ruby/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-pantumor02/>, <https://onco.cc/targets/her2/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/> .